Dongcheng Biochem(SZ:002675) Xin Lang Cai Jing·2026-02-26 01:29Group 1 - Dongcheng Pharmaceutical's stock increased by 0.97% on February 25, with a trading volume of 112 million yuan. The financing buy amount was 14.88 million yuan, while the financing repayment was 9.10 million yuan, resulting in a net financing buy of 5.78 million yuan. The total financing and securities balance reached 1.075 billion yuan as of February 25 [1] - The financing balance of Dongcheng Pharmaceutical is 1.075 billion yuan, accounting for 9.65% of the circulating market value, which is above the 70th percentile level over the past year, indicating a relatively high position [1] - On the same day, there were no shares repaid or sold in the securities lending market, with a remaining amount of 12,900 shares and a securities lending balance of 174,100 yuan, which is below the 10th percentile level over the past year, indicating a low position [1] Group 2 - As of September 30, the number of shareholders of Dongcheng Pharmaceutical was 24,600, an increase of 4.51% compared to the previous period. The average circulating shares per person decreased by 4.32% to 30,191 shares [2] - For the period from January to September 2025, Dongcheng Pharmaceutical reported operating revenue of 2.043 billion yuan, a year-on-year decrease of 5.52%. The net profit attributable to the parent company was 149 million yuan, down 10.64% year-on-year [2] - Since its A-share listing, Dongcheng Pharmaceutical has distributed a total of 1 billion yuan in dividends, with 293 million yuan distributed over the past three years. As of December 31, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 20.2793 million shares, an increase of 252,100 shares compared to the previous period [3]